Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IPXL's Cash to Debt is ranked higher than
99% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. IPXL: No Debt )
IPXL' s 10-Year Cash to Debt Range
Min: 0.73   Max: No Debt
Current: No Debt

Equity to Asset 0.82
IPXL's Equity to Asset is ranked higher than
88% of the 843 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. IPXL: 0.82 )
IPXL' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.82
Current: 0.82

0.12
0.82
Interest Coverage 2065.49
IPXL's Interest Coverage is ranked higher than
73% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. IPXL: 2065.49 )
IPXL' s 10-Year Interest Coverage Range
Min: 0.82   Max: 9999.99
Current: 2065.49

0.82
9999.99
F-Score: 6
Z-Score: 12.39
M-Score: -2.24
WACC vs ROIC
12.81%
12.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 14.90
IPXL's Operating margin (%) is ranked higher than
84% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.26 vs. IPXL: 14.90 )
IPXL' s 10-Year Operating margin (%) Range
Min: -1418.74   Max: 44.72
Current: 14.9

-1418.74
44.72
Net-margin (%) 9.62
IPXL's Net-margin (%) is ranked higher than
80% of the 869 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.01 vs. IPXL: 9.62 )
IPXL' s 10-Year Net-margin (%) Range
Min: -1376.35   Max: 46
Current: 9.62

-1376.35
46
ROE (%) 6.70
IPXL's ROE (%) is ranked higher than
75% of the 894 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.27 vs. IPXL: 6.70 )
IPXL' s 10-Year ROE (%) Range
Min: -341.31   Max: 125.75
Current: 6.7

-341.31
125.75
ROA (%) 5.51
IPXL's ROA (%) is ranked higher than
80% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.27 vs. IPXL: 5.51 )
IPXL' s 10-Year ROA (%) Range
Min: -70.9   Max: 38.8
Current: 5.51

-70.9
38.8
ROC (Joel Greenblatt) (%) 27.32
IPXL's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 920 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.87 vs. IPXL: 27.32 )
IPXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -297.18   Max: 235.82
Current: 27.32

-297.18
235.82
Revenue Growth (3Y)(%) 3.50
IPXL's Revenue Growth (3Y)(%) is ranked higher than
70% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. IPXL: 3.50 )
IPXL' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 203.4
Current: 3.5

0
203.4
EBITDA Growth (3Y)(%) 1.60
IPXL's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.10 vs. IPXL: 1.60 )
IPXL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 61.6
Current: 1.6

0
61.6
EPS Growth (3Y)(%) -5.80
IPXL's EPS Growth (3Y)(%) is ranked higher than
69% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.30 vs. IPXL: -5.80 )
IPXL' s 10-Year EPS Growth (3Y)(%) Range
Min: -32.2   Max: 55.1
Current: -5.8

-32.2
55.1
» IPXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

IPXL Guru Trades in Q1 2014

John Hussman 220,000 sh (New)
Steven Cohen 63,998 sh (+266.25%)
Paul Tudor Jones 18,000 sh (+62.16%)
Jim Simons 1,046,000 sh (-25.73%)
RS Investment Management 1,328,437 sh (-43.48%)
» More
Q2 2014

IPXL Guru Trades in Q2 2014

NWQ Managers 984,841 sh (New)
John Hussman 310,000 sh (+40.91%)
Paul Tudor Jones 18,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management 940,950 sh (-29.17%)
» More
Q3 2014

IPXL Guru Trades in Q3 2014

Jim Simons 39,400 sh (New)
Joel Greenblatt 33,709 sh (New)
Paul Tudor Jones 36,853 sh (+104.74%)
NWQ Managers 1,298,995 sh (+31.90%)
RS Investment Management 809,959 sh (-13.92%)
John Hussman 250,000 sh (-19.35%)
» More
Q4 2014

IPXL Guru Trades in Q4 2014

Mario Gabelli 6,775 sh (New)
Alan Fournier 533,100 sh (New)
Joel Greenblatt 79,609 sh (+136.17%)
Jim Simons 61,400 sh (+55.84%)
Paul Tudor Jones 39,050 sh (+5.96%)
John Hussman 250,000 sh (unchged)
RS Investment Management Sold Out
NWQ Managers 906,043 sh (-30.25%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 57.90
IPXL's P/E(ttm) is ranked higher than
72% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 52.50 vs. IPXL: 57.90 )
IPXL' s 10-Year P/E(ttm) Range
Min: 4.04   Max: 1043
Current: 57.9

4.04
1043
Forward P/E 31.85
IPXL's Forward P/E is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.73 vs. IPXL: 31.85 )
N/A
PE(NRI) 56.30
IPXL's PE(NRI) is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 51.50 vs. IPXL: 56.30 )
IPXL' s 10-Year PE(NRI) Range
Min: 4.04   Max: 1043
Current: 56.3

4.04
1043
P/B 3.70
IPXL's P/B is ranked higher than
69% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. IPXL: 3.70 )
IPXL' s 10-Year P/B Range
Min: 1.32   Max: 14.47
Current: 3.7

1.32
14.47
P/S 5.50
IPXL's P/S is ranked higher than
57% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.38 vs. IPXL: 5.50 )
IPXL' s 10-Year P/S Range
Min: 1.17   Max: 12.72
Current: 5.5

1.17
12.72
POCF 97.32
IPXL's POCF is ranked higher than
70% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.96 vs. IPXL: 97.32 )
IPXL' s 10-Year POCF Range
Min: 1.75   Max: 2002
Current: 97.32

1.75
2002
EV-to-EBIT 32.06
IPXL's EV-to-EBIT is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.80 vs. IPXL: 32.06 )
IPXL' s 10-Year EV-to-EBIT Range
Min: -642.3   Max: 628.6
Current: 32.06

-642.3
628.6
Shiller P/E 29.30
IPXL's Shiller P/E is ranked higher than
86% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 116.82 vs. IPXL: 29.30 )
IPXL' s 10-Year Shiller P/E Range
Min: 10.16   Max: 61.99
Current: 29.3

10.16
61.99
Current Ratio 4.60
IPXL's Current Ratio is ranked higher than
85% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. IPXL: 4.60 )
IPXL' s 10-Year Current Ratio Range
Min: 0.34   Max: 5.64
Current: 4.6

0.34
5.64
Quick Ratio 4.10
IPXL's Quick Ratio is ranked higher than
86% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. IPXL: 4.10 )
IPXL' s 10-Year Quick Ratio Range
Min: 0.34   Max: 5.19
Current: 4.1

0.34
5.19
Days Inventory 102.46
IPXL's Days Inventory is ranked higher than
82% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.83 vs. IPXL: 102.46 )
IPXL' s 10-Year Days Inventory Range
Min: 50.25   Max: 398.94
Current: 102.46

50.25
398.94
Days Sales Outstanding 89.71
IPXL's Days Sales Outstanding is ranked higher than
71% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 78.61 vs. IPXL: 89.71 )
IPXL' s 10-Year Days Sales Outstanding Range
Min: 34.05   Max: 1169.47
Current: 89.71

34.05
1169.47

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.90
IPXL's Price/Net Cash is ranked higher than
88% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 14.90 )
IPXL' s 10-Year Price/Net Cash Range
Min: 7.74   Max: 14.67
Current: 14.9

7.74
14.67
Price/Net Current Asset Value 8.90
IPXL's Price/Net Current Asset Value is ranked higher than
90% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IPXL: 8.90 )
IPXL' s 10-Year Price/Net Current Asset Value Range
Min: 3.28   Max: 14.36
Current: 8.9

3.28
14.36
Price/Tangible Book 4.00
IPXL's Price/Tangible Book is ranked higher than
74% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. IPXL: 4.00 )
IPXL' s 10-Year Price/Tangible Book Range
Min: 1.45   Max: 26.35
Current: 4

1.45
26.35
Price/DCF (Projected) 3.40
IPXL's Price/DCF (Projected) is ranked higher than
81% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.70 vs. IPXL: 3.40 )
IPXL' s 10-Year Price/DCF (Projected) Range
Min: 1.41   Max: 3.82
Current: 3.4

1.41
3.82
Price/Median PS Value 1.80
IPXL's Price/Median PS Value is ranked higher than
63% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. IPXL: 1.80 )
IPXL' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 26.88
Current: 1.8

0.48
26.88
Price/Graham Number 3.20
IPXL's Price/Graham Number is ranked higher than
79% of the 964 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.78 vs. IPXL: 3.20 )
IPXL' s 10-Year Price/Graham Number Range
Min: 0.79   Max: 2.18
Current: 3.2

0.79
2.18
Earnings Yield (Greenblatt) 3.00
IPXL's Earnings Yield (Greenblatt) is ranked higher than
76% of the 918 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. IPXL: 3.00 )
IPXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 55.9
Current: 3

0.2
55.9
Forward Rate of Return (Yacktman) -22.26
IPXL's Forward Rate of Return (Yacktman) is ranked higher than
55% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.09 vs. IPXL: -22.26 )
IPXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.3   Max: 61
Current: -22.26

-22.3
61

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:ILR.Germany,
Impax Laboratories, Inc., is a Delaware corporation was incorporated in 1995. It is a technology-based, specialty pharmaceutical company applying formulation and development expertise, as well as its drug delivery technology, to the development, manufacture and marketing of bioequivalent pharmaceutical products, commonly referred to as 'generics' in addition to the development and marketing of branded products. The Company operates in two segments namely Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Division develops, manufactures, sells and distributes its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are usually marketed under their established nonproprietary drug names rather than by a brand name. The Company develops, manufacture, sell and distribute specialty generic pharmaceuticals. The Global Division develops, manufactures, sells, and distributes generic pharmaceutical products mainly through four sales channels: the 'Global products' sales channel, for generic pharmaceutical prescription products the Company sells directly to wholesalers, large retail drug chains, and others; the 'Private Label' sales channel, for generic pharmaceutical over-the-counter ('OTC') and prescription products the Company sells to unrelated third-party customers who in-turn sell the product to third parties under its own label; the 'Rx Partner' sales channel, for generic prescription products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements; and the 'OTC Partner' sales channel, for sales of generic pharmaceutical OTC products sold through unrelated third-party pharmaceutical entities under its own label pursuant to alliance agreements. The Impax Division is engaged in the development of proprietary brand pharmaceutical products. The Impax Division is also engaged in the sale and distribution of branded Zomig(r) (zolmitriptan) products, indicated for the treatment of migraine headaches, under the terms of a Distribution, License, Development and Supply Agreement (AZ Agreement) with AstraZeneca UK Limited (AstraZeneca). The Company's Impax Division develops proprietary brand pharmaceutical products through improvements to already approved pharmaceutical products to address central nervous system ('CNS') disorders. The Impax Division is also engaged in the co-promotion through a direct sales force focused on marketing to physicians, mainly in the CNS community, pharmaceutical products developed by other unrelated third-party pharmaceutical entities. The Company markets and sells its generic pharmaceutical prescription drug products within the continental United States of America and the Commonwealth of Puerto Rico. The chemical raw materials, essential to its business, are generally readily available from multiple sources in the U.S. and throughout the world. Generic pharmaceutical product deve
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
comment on IPXL Sep 24 2012 
President and CEO of Impax Laboratories Inc. (IPXL) Larry Hsu Bought 10,000 Shares Aug 17 2011 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 5,000 Shares Aug 12 2010 
Impax Laboratories Inc. (IPXL) CEO Larry Hsu buys 10,000 Shares Aug 12 2010 
Impax Laboratories Reports Second Quarter 2009 Financial Results Aug 04 2009 

More From Other Websites
Generic Companies Are Fighting for Market Share Mar 28 2015
What’s Supporting Continued Growth in the Generics Market? Mar 28 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Mar 25 2015
Is a Para IV Filing Rewarding for a Generic Company? Mar 25 2015
Regulations Are Instrumental in the Marketing Authorization Process Mar 25 2015
Why Is the Generics Industry Controlled by Regulations? Mar 25 2015
Two Future Leaders of Specialty Pharma Mar 23 2015
What Two Factors Are Driving the US Generics Market? Mar 23 2015
Why the Generic Industry’s Classification Is Still Evolving Mar 19 2015
Are Generics the Only Affordable Drugs? Mar 19 2015
Actavis Receives FDA Approval for Saphris' Label Expansion - Analyst Blog Mar 16 2015
ACADIA Down on Nuplazid NDA Delay and CEO Resignation - Analyst Blog Mar 13 2015
Actavis' Generic Pulmicort on Hold until Final Verdict - Analyst Blog Mar 13 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Mar 12 2015
Supernus Gains on Solid Q4 Earnings, Encouraging Guidance - Analyst Blog Mar 12 2015
IMPAX LABORATORIES INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Mar 10 2015
Impax to Present at the Cowen and Company 35th Annual Health Care Conference Mar 10 2015
Impax Completes Acquisition Of Tower Holdings, Inc. And Lineage Therapeutics Inc. Mar 10 2015
Impax Completes Acquisition Of Tower Holdings, Inc. And Lineage Therapeutics Inc. Mar 10 2015
Mallinckrodt to Acquire Ikaria, Expand into Hospital Market - Analyst Blog Mar 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK